Posted in Artificial Intelligence in Medicine - Applications in Therapeutics, Big Data, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Drug Development Process, Intelligent Information Systems, Natural Language Processing (NLP), Pha...
Indeed, a near-consensus is emerging in favor of explainable AI/ML among academics, governments, and civil society groups. Many are drawn to this approach to harness the accuracy benefits of noninterpretable AI/ML such as deep learning or neural nets while also supporting transparency, trust, ...
dear sir i am m.pharma student and i start my own company on the basis of loan license so please give me information to getting the loan license and start company suraj kokatesaid on June 26, 2011 dear sir, i'm a medical rep. in yavatmal, and i want to start my own pharma company...
Terpenoids, also referred to as terpenes, are the largest group of natural compounds. Many terpenes have biological activities and are used for the treatment of human diseases. The worldwide sales of terpene-based pharmaceuticals in 2002 were approximate
The concept of “one size fits all” followed by the conventional healthcare system has drawbacks in providing precise pharmacotherapy due to variation in the pharmacokinetics of different patients leading to serious consequences such as side effects. In this regard, digital-based three-dimensional prin...
India, which has the world's third largest pharmaceutical industry, rep- resents a smaller yet still sizeable share of global antibiotic API manufacturing. Indian companies have also positioned themselves as leaders in the production of 'finished dose' antibiotic products using APIs mainly imported ...
Chief Research & Development Officer, Replimune 2002 in UK promise in oncolytic therapy GNCSF Phase III melanoma 2015 M&A with Amgen oncolytic therapy remains non effecting on immune response data is key for commercialization do not belief in systemic therapy achieve maximum immune response possibl...
) set to launch this year, with a 2022 sales forecast of $1.22 billion. Some of the peak sales estimates range significantly higher as analysts crunch the numbers on a disease that afflicts only about 30,000 people worldwide. PATENT WO 2016033326 https://patents.google.com/patent/WO20160333...
Chief Research & Development Officer, Replimune 2002 in UK promise in oncolytic therapy GNCSF Phase III melanoma 2015 M&A with Amgen oncolytic therapy remains non effecting on immune response data is key for commercialization do not belief in systemic therapy achieve maximum immune response possibl...
re-focusing on emerging markets, where AZ already gets $6 billion in sales, especially China. But the short-term key to delivering on his promises today seems to come down to a single drug: Brilinta, the Plavix competitor thatAstraZeneca introduced in 2011 which has so far disappointed, gene...